Šalis: Kanada
kalba: anglų
Šaltinis: Health Canada
MEDROXYPROGESTERONE ACETATE
APOTEX INC
G03DA02
MEDROXYPROGESTERONE
5MG
TABLET
MEDROXYPROGESTERONE ACETATE 5MG
ORAL
100/500
Prescription
PROGESTINS
Active ingredient group (AIG) number: 0106339005; AHFS:
APPROVED
2001-11-02
Page 1 of 39 PRODUCT MONOGRAPH Pr APO-MEDROXY (MEDROXYPROGESTERONE ACETATE TABLETS USP) 2.5 MG, 5 MG, 10 MG AND 100 MG PROGESTIN APOTEX INC. 150 Signet Drive Toronto, Ontario Date of Revision: M9L 1T9 July 21, 2017 CONTROL NO. 207292 Page 2 of 39 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................... 4 ADVERSE REACTIONS ....................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................... 15 DOSAGE AND ADMINISTRATION ................................................................................... 17 OVERDOSAGE ...................................................................................................................... 19 ACTION AND CLINICAL PHARMACOLOGY.................................................................. 19 STORAGE AND STABILITY ............................................................................................... 22 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................. 23 PART II: SCIENTIFIC INFORMATION ............................................................................. 24 PHARMACEUTICAL INFORMATION ............................................................................... 24 CLINICAL TRIALS ............................................................................................................... 24 DETAILED PHARMACOLOGY ................................. Perskaitykite visą dokumentą